novo nordisk, eli lilly have strong first-mover advantage: analyst
Published 4 months ago • 1.4K plays • Length 3:45Download video MP4
Download video MP3
Similar videos
-
4:17
barclays: novo nordisk and eli lilly have first-move advantage in the obesity drug race
-
2:49
eli lilly and novo nordisk are ahead in manufacturing but need time to meet demand, says louise chen
-
4:35
jim cramer weighs the market impact of eli lilly and novo nordisk's weight loss drugs
-
5:47
zealand's obesity drug shouldn't disrupt novo nordisk-eli lilly leadership: mizuho's jared holz
-
6:14
new developments in weight-loss drugs: novo nordisk, eli lilly & pfizer advance studies
-
22:32
forecast for 2025 fed cuts | bloomberg real yield 11/22/2024
-
44:32
why do groceries cost so much? | cnbc marathon
-
12:14
how much money do americans need to be comfortable?
-
5:53
eli lilly and novo nordisk will remain leaders in the weight-loss drug market: mizuho's jared holz
-
6:43
eli lilly ceo on weight loss drugs outlook: our top priority is making more product
-
2:34
eli lilly stock tumbles 10% after drug giant misses estimates and slashes profit guidance
-
0:59
eli lilly ceo on why food companies haven't seen a big impact on sales
-
2:49
u.s. doctors are 'wowed' by novo nordisk's weight-loss drug data, analyst says
-
1:41
eli lilly to build $4.5 billion research and manufacturing center to propel drug pipeline
-
5:27
eli lilly's drop after earnings is a buying opportunity, says mizuho's jared holz
-
3:54
former fda commissioner: expect more competition in eli lilly and novo nordisk's weight-loss drugs
-
19:20
how ozempic and wegovy accidentally made novo nordisk a $400b company
-
3:30
goldman sachs raises target on eli lilly: here's why
-
3:39
what eli lilly, novo nordisk earnings show about glp-1 sales
-
6:13
obesity weight loss market will remain a duopoly between novo nordisk and eli lilly: bofa’s meacham
-
2:49
jim cramer explains why he favors eli lilly in the weight loss drug space
-
3:45
three-stock lunch: eli lilly, transdigm, & nvidia